Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00216294

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

Obsessive Compulsive Disorder (OCD) Clinical Trial

Official title:
An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on OCD patients' anxiety, quality of life, and depression.

Clinical Trial Description

This is an open-label, dose-escalation pilot study. Prospective participants will initially undergo a blinded placebo challenge to assess his or her ability to self-administer drug. A total of sixteen subjects, will be enrolled in one of two study arms (eight subjects per group), depending on whether or not they are receiving concurrent treatment with a Selective Serotonin Reuptake Inhibitor (SSRI). The first 8 patients enrolled will receive subcutaneous injections of RG1068 at 10 µg/kg and will be divided between those receiving SSRI's and those not receiving SSRI's. Those not receiving SSRI treatment will further be divided between newly diagnosed, SSRI-naïve patients and patients who received SSRI's in the past but who have discontinued treatment for at least twelve weeks prior to enrollment. If there are no drug-related serious adverse events, an additional eight patients will be enrolled and receive RG1068 at 20 µg/kg. This group will also be divided between those receiving SSRI's and those not receiving SSRI's. Those not receiving SSRI treatment will be further divided in the same manner as before; newly diagnosed, SSRI-naïve patients, and patients who received SSRI's in the past but who have discontinued treatment for at least twelve weeks prior to enrollment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00216294
Study type Interventional
Source Indiana University
Contact
Status Completed
Phase Phase 2
Start date February 2005
Completion date April 2006
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02886780 - "Concentrated Exposure Treatment" (cET) for for Obsessive Compulsive Disorder N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Recruiting NCT05240924 - ERP to Improve Functioning in Veterans With OCD N/A
Completed NCT03476902 - Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD N/A
Completed NCT01617083 - Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Phase 2
Completed NCT01447966 - Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder N/A
Recruiting NCT02528331 - Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study N/A
Completed NCT04432246 - Electroencephalography Predictors of Repetitive Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder N/A
Not yet recruiting NCT02160431 - Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD) N/A
Completed NCT02656784 - The Efficacy of TBCT Compared to ERP in the Treatment of OCD Patients, by the Assessment of Magnetic Resonance. N/A
Recruiting NCT01879254 - Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD). N/A
Active, not recruiting NCT02216981 - Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD N/A
Recruiting NCT05160129 - Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder N/A